At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 941 enrolled
Drug / intervention
olmesartan medoxomil +2 moredrug
Likely dose
olmesartan medoxomil 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Active-comparator, 8-week Forced-titration Study of the Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Hypertensive Subjects
In Brief
A Phase 4 clinical trial evaluating olmesartan medoxomil, Placebo, and 1 other intervention for Hypertension. Completed, enrolled 941 participants across 20 sites.
Detailed Summary
This study will evaluate the efficacy and safety of the FDA approved blood pressure medication olmesartan medoxomil compared to the FDA approved medication losartan potassium.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2009
Enrollment StartAug 2009
Primary CompletionJan 2010
TodayJul 2026
First PostedJul 30, 2009
Enrollment StartAug 1, 2009
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 16.9 years ago
Interventions
olmesartan medoxomildrug
Oral tablets, once daily, at either 20mg or 40mg daily.
Placebodrug
placebo oral tablets once daily for two weeks
losartan potassiumdrug
losartan potassium oral tablet at either 50mg or 100 mg daily dose.